RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Comparing Corporate Presentations i agree wino, i know i come across very negative most times, it comes from me comparing to even other small cap bio's and there approach to gaining traction with the investment community outside of institutions. I would be the first to admit that, however i have not always felt this way as it is a direct result of the company's unwillingness to change their approach. I have have multiple conversations with phillipe. I think he is a good person first and foremost and is probably good at the number and accounting ect. But when we talked i would ask alot of questions and most answers were defensive. I would assume they were because I wasn't the first to point certain things out. Since my very first encounter i found him to be extremely pleasant but his forte is not selling the story point blank. Paul isnt the "seller" of the story either although i think he is a good face for the company and very positive and upbeat. They simply do not focus on the right subjects when they are updating the market on operations. Ive seen time after time when a big piece of info was buried in the 3rd paragraph of a pr. So i have a very sour taste in my mouth when people like yourself and rusty who have many years combined in the investment world giving sound advise they pretty much ignore it. All that said im still here not because of hope but belief that i the research and dd that ive done on top of all the sound analysis here that it will pay off it just appears that it could be maximized much better through a different approach.
Wino115 wrote:
and that was just for the one FDA filed indication of breast cancer. They would have to pay more for endometrial and whatever else Gilead gets approved. Gilead may or may not be bound to a "first-right" to Everest for new indications.
LouisW wrote: To me, the 10%, annual rate of interest is super high to me, that may also serverely jeopardize the profit as well. Hopes the deal with China company brings us a bunch of cash.
FYI, when Immunomedics and Everest Medicines Announce Exclusive License Agreement for Sacituzumab Govitecan, Immunomedics receive up-front payment of $65 million and an additional $60 million based on U.S. FDA approval of sacituzumab govitecan.as well as Potential Development, Regulatory, and Sales Milestone Payments Totaling $710 Million and Escalating Tiered Royalties that Begin in the Mid-Teens on Net Sales within the Territory. The deal was done when the phase 2 trial was ongoing.